Clinical Trial Results:
A non-inferiority study on dose reduction of adalimumab in psoriasis patients who are overtreated.
Summary
|
|
EudraCT number |
2019-001918-42 |
Trial protocol |
BE |
Global end of trial date |
22 Mar 2022
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Aug 2024
|
First version publication date |
02 Aug 2024
|
Other versions |
|
Summary report(s) |
Final Study Report |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
TDM-ADA2019
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04028713 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
UZ Gent - HIRUZ
|
||
Sponsor organisation address |
C. Heymanslaan 10, Gent, Belgium, 9000
|
||
Public contact |
HIRUZ CTU, Ghent University Hospital, hiruz.ctu@uzgent.be
|
||
Scientific contact |
HIRUZ CTU, Ghent University Hospital, 32 093320530, hiruz.ctu@uzgent.be
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
22 Mar 2022
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
22 Mar 2022
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
- The proportion of patients in each group in clinical remission (absolute PASI < 2) at year 1 after optimization (non-inferiority of intervention)
- Optimization of extraction protocol for adalimumab serum trough levels and anti-drug antibodies (ADA) derived from micro-sampling technique.
|
||
Protection of trial subjects |
See attachment Final Study Report
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
31 Dec 2019
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 19
|
||
Worldwide total number of subjects |
19
|
||
EEA total number of subjects |
19
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
16
|
||
From 65 to 84 years |
3
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
See attachment Final Study Report | |||||||||
Pre-assignment
|
||||||||||
Screening details |
See attachment Final Study Report | |||||||||
Period 1
|
||||||||||
Period 1 title |
Overal Trial (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Single blind | |||||||||
Roles blinded |
Investigator [1] | |||||||||
Blinding implementation details |
See attachment Final Study Report
|
|||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
Intervention | |||||||||
Arm description |
See attachment Final Study Report | |||||||||
Arm type |
Active comparator | |||||||||
Investigational medicinal product name |
Adalimumab
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
|||||||||
Routes of administration |
Subcutaneous use
|
|||||||||
Dosage and administration details |
See attachment Final Study Report
|
|||||||||
Arm title
|
Standard dosing arm | |||||||||
Arm description |
See attachment Final Study Report | |||||||||
Arm type |
Active comparator | |||||||||
Investigational medicinal product name |
Adalimumab
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
|||||||||
Routes of administration |
Subcutaneous use
|
|||||||||
Dosage and administration details |
See attachment Final Study Report
|
|||||||||
Notes [1] - The roles blinded appear inconsistent with a simple blinded trial. Justification: See attachment Final Study Report |
||||||||||
|
||||||||||
Notes [2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same. Justification: See attachment Final Study Report |
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Intervention
|
||
Reporting group description |
See attachment Final Study Report | ||
Reporting group title |
Standard dosing arm
|
||
Reporting group description |
See attachment Final Study Report |
|
||||||||||
End point title |
Primary [1] | |||||||||
End point description |
See attachment Final Study Report
|
|||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
During the study
|
|||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: For statistical analyses, see attachment Final Study Report |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Secondary | |||||||||
End point description |
See attachment Final Study Report
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
During the study
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
During the study
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
0
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: See attachment Final Study Report |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |